Anzeige
Mehr »
Samstag, 07.03.2026 - Börsentäglich über 12.000 News
USA erklären Kupfer zur Chefsache - dieser Nevada-Explorer bohrt bereits
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Investing.com

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
04:18FDA approves Sotyktu for active psoriatic arthritis treatment
02:30Cathie Wood's ARK sells Roku stock, buys Joby Aviation and Robinhood on March 6th
02:18Nvidia ties CEO Huang's $4M bonus to 2027 revenue milestones
01:54AMC Networks secures 99.8% bondholder consent for debt changes
01:54AMC Networks completes debt exchange offer with 95% participation
01:54AMC Networks secures 99.8% bondholder consent for debt amendments
00:54Venu Holding plans public offering of stock and warrants
00:30Lisata Therapeutics agrees to $5 per share acquisition by Kuva Labs
00:18XAI Octagon trust announces 1-for-5 reverse stock split
FrEversource awaits final decision on Aquarion sale to water authority
FrOppenheimer reiterates Immuneering stock rating on pipeline progress
FrAMC secures $425M credit facility to refinance Odeon debt
FrCanaccord reiterates Heartflow stock Buy rating at $40 target
FrTruist cuts Genesco stock price target on macro caution
FrDeFi Technologies receives Nasdaq bid price deficiency notice
FrNerdy receives NYSE non-compliance notice on stock price
FrBofA cuts Western Alliance stock price target on credit quality
FrJefferies cuts Genesco stock price target on margin pressures
FrTD Cowen lowers Owlet stock price target to $13 on Q1 guidance
FrTruist maintains Vail Resorts stock rating ahead of earnings
FrEuropean Commission approves Zynyz for anal cancer treatment
FrJefferies reiterates Hudson Pacific Properties stock Hold rating
FrTruist holds Essex Property stock rating on low supply outlook
FrJefferies reiterates Boeing stock buy rating on China order talks
FrRaymond James reiterates Legend Biotech stock rating after rival approval